| Drug Name |
Letermovir |
| Drug ID |
BADD_D02502 |
| Description |
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients [L1021]. It represents the first entry into a new class of CMV anti-infectives, DNA terminase complex inhibitors [A31290]. Letermovir has recieved both priority and orphan drug status from the FDA. It is currently marketed under the brand name Prevymis [L1021]. |
| Indications and Usage |
For use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT) [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AX18 |
| DrugBank ID |
DB12070
|
| KEGG ID |
D10801
|
| MeSH ID |
C000588473
|
| PubChem ID |
45138674
|
| TTD Drug ID |
D0G8PA
|
| NDC Product Code |
69497-0128; 50473-0126; 50473-0127; 0006-3076; 0006-5004; 0006-5003; 0006-3075 |
| UNII |
1H09Y5WO1F
|
| Synonyms |
letermovir | Prevymis | AIC246 |
